Researchers at the University of California, Santa Barbara have discovered that attaching polymeric nanoparticles to the surface of red blood cells dramatically increases the in vivo lifetime of the nanoparticles. The research, published in the July 07 issue of Experimental Biology and Medicine, could offer applications for the delivery of drugs and circulating bioreactors.
“Attachment of polymeric nanoparticles to red blood cells combines the advantages of the long circulating lifetime of the red blood cell, and their abundance, with the robustness of polymeric nanoparticles,” said Mitragotri. “Using red blood cells to extend the circulation time of the particles avoids the need to modify the surface chemistry of the entire particle, which offers the potential to attach chemicals to the exposed surface for targeting applications.”
The researchers say that it may be possible to keep the nanoparticles in circulation for a relatively long time, theoretically up to the circulation lifetime of a red blood cell – which is 120 days – if the binding between particles and the red blood cells is strengthened. The methodology is applicable to drugs that are effective while still attached to a red blood cell, although the researchers say that slow release from the red blood cell surface is also feasible.
Mitragotri says “this mode of prolonging particle circulation has significant implications in drug delivery, potentially leading to new treatments for a broad variety of conditions such as cancer, blood clots and heart disease”. Dr. Steven R. Goodman.
Polymer nanoparticles attach to red blood cells and remain in circulation for prolonged times. Unattached nanoparticles are rapidly cleared by body’s immune system. Credit: Image prepared by Mr. Peter Allen, UCSB. Society for Experimental Biology and Medicine
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.